MedTrace Logo

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

NCT03920839 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-04-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.

Conditions

  • Advanced and/or Metastatic Solid Tumors
  • Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
  • Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Interventions

DRUG

Retifanlimab

INCMGA00012 administered intravenously every 3 weeks.

DRUG

Gemcitabine

Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.

DRUG

Cisplatin

Cisplatin administered intravenously on Day 1 of 21-day cycles.

DRUG

Pemetrexed

Pemetrexed administered intravenously on Day 1 of 21-day cycles.

DRUG

Carboplatin

Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.

DRUG

Paclitaxel

Paclitaxel administered intravenously on Day 1 of 21-day cycles.

Sponsors & Collaborators

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2019-11-04
Completion
2019-11-04
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920839 on ClinicalTrials.gov